↓
 

Drug Pipeline and Conference Coverage

Hepatitis C Drug Pipeline

Drug Pipeline and Conference Coverage
  • Home
  • Clinical Trials Site
  • Commonly Used Terms
  • Category Tree
  • Drug Pipeline
  • HepC Medications Blog

Category Archives: sunitinib (sutent)

Sorafenib benefit dependent on hepatitis status in patients with HCC

Drug Pipeline and Conference Coverage

Sorafenib improved OS among patients with hepatocellular carcinoma who were hepatitis C positive but hepatitis B negative, suggesting that the beneficial effects of sorafenib may be based on hepatitis status, according to results of a meta-analysis.

“Irrespective of the mechanism, our data suggest that in future trials in HCC, particularly where sorafenib is the control arm, there should be stratification according to etiology,” Richard Jackson, BSc, MSc, from the Liverpool Cancer Trials Unit of University of Liverpool in United Kingdom, and colleagues wrote. “Etiological differences have already been considered as factors in the interpretation of clinical trials.”

The analysis included 3,256 patients with HCC treated in three randomized phase 3 clinical trials that compared sorafenib (Nexavar, Bayer) with brivanib (BMS-540215, Bristol-Myers Squibb; n = 1,155), sunitinib (Sutent, Pfizer; n = 1,070) or linifanib (ABT-869, Abbott; n = 1,031).

Read more

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
Facebooktwitter

Search this site . . .

Last Updated

This Reference Guide was last updated on 4/20/2018

Select a Category

Share This Site

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow HCV Advocate

Facebooktwitter
© 2016 HCVAdvocate.org
↑